About John Doyle
At the Swiss Biotech conference on May 17, 2025, John Doyle, Chief Scientific Officer and President of Consulting at Fortrea Holdings, discussed value optimization for biotech companies. He argued that companies should think "holistically about value," moving beyond a focus on clinical value to consider patient or humanistic value, as well as economic value. Doyle noted that humanistic value can be measured through traditional methods like clinical outcome assessments and patient-reported outcomes, as well as emerging techniques using digital health technology and wearables that generate patient experience data passively.
Doyle stated that economic value must be demonstrated with evidence, and that companies often need to translate clinical and humanistic value into economic terms to be measured and rewarded by payers and health technology assessment agencies. He observed that the industry is moving toward a "convergence of regulatory review as well as value appraisal," and that biotech companies can now focus on generating value for multiple stakeholders simultaneously.
Source: AI-verified profile updated from John Doyle's recent appearances.
Browse all interviews →
Transcript (1 segments)
J
John Doyle0:00
Today we are going to talk a little bit about value optimization for biotech companies. And what's exciting about value optimization is that it really gets you thinking holistically about value. I think often we're hyper focused on clinical value, and obviously it makes perfect sense to start there but not end there. There are a lot of elements to value that biotech companies should consider to ensure that they're optimizing the value of their assets and their company. Some other examples. You want to think about patient value or humanistic value. And there's many ways to measure humanistic value these days, some with traditional techniques like clinical outcome assessments. PROs. There's also emerging techniques using digital health technology and wearables and sensors that generate patient experience data passively, not always actively asking them, but just monitoring them in terms of how they're interacting with the world around them. That's an important element of value that many biotech companies create with their assets, is this better experience value. Another thought around value is maybe an obvious one, but it's economic value. But it needs to be measured. You need evidence to demonstrate economic value. And often you have to convert or translate your clinical and your humanistic value in economic terms so that it can be measured and rewarded by payers and health technology assessment agencies. And where the world is going is really around convergence of regulatory review as well as value appraisal. Biotech companies now can focus on generating value for multiple stakeholders simultaneously.
